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ABSTRACT Digital technologies are increasingly harnessed to support treatment of persons with
tuberculosis (TB). Since in-person directly observed treatment (DOT) can be resource intensive and
challenging to implement, these technologies may have the potential to improve adherence and clinical
outcomes. We reviewed the effect of these technologies on TB treatment adherence and patient outcomes.
We searched several bibliographical databases for studies reporting the effect of digital interventions,
including short message service (SMS), video-observed therapy (VOT) and medication monitors (MMs),
to support treatment for active TB. Only studies with a control group and which reported effect estimates
were included.
Four trials showed no statistically significant effect on treatment completion when SMS was added to
standard care. Two observational studies of VOT reported comparable treatment completion rates when
compared with in-person DOT. MMs increased the probability of cure (RR 2.3, 95% CI 1.6–3.4) in one
observational study, and one trial reported a statistically significant reduction in missed treatment doses
relative to standard care (adjusted means ratio 0.58, 95% CI 0.42–0.79).
Evidence of the effect of digital technologies to improve TB care remains limited. More studies of better
quality are needed to determine how such technologies can enhance programme performance.
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Introduction
Digital technologies are changing healthcare delivery globally, as witnessed by the dramatic growth in such
areas as electronic health records, telehealth for “virtual” patient encounters, and teleradiology for remote
interpretation of imaging studies [1]. There is also increasing recognition that digital technologies can
support medication adherence. Examples include the use of video phone calls for observation of
medication ingestion, and for live discussion of any problems or concerns; the use of short message service
((SMS), i.e. text messaging) for ongoing communication between patients and providers; and the use of
SMS or electronic medication monitors (MMs) for automatic reminders, and/or for real-time monitoring
of medication self-administration which is then fed back to providers. MMs most commonly take the form
of “smart” pill bottles, which can keep track of pill counts and bottle openings, and transmit adherence
reports to treating health professionals [2–4].
Digital treatment support can lead to better treatment results in patients with chronic diseases, such as
diabetes [5–7]. As with tuberculosis (TB), these chronic conditions require long-term commitment to
treatment by patients and caregivers. Several systematic reviews aimed at measuring the effectiveness of
mobile communication technologies, such as SMS, have also documented improved adherence to
antiretroviral treatment [8], and higher rates of smoking cessation [9]. Other studies evaluating SMS-based
interventions in maternal–child health services [10, 11] found improved contraceptive pill adherence [12]
and higher proportions of deliveries by trained personnel [13].
Suboptimal adherence to TB treatment is common, with a global treatment success rate of 75% for new
and relapse TB cases in 2014 [14], despite long-standing support for strategies such as direct observation
to help patients complete their treatment[15]. While barriers to adherence have been much researched,
there has been little progress in lessening treatment burden by mitigating frequent adverse reactions, or
substantially shortening the duration of current regimens; minimum 6 months for drug-susceptible TB
(DS-TB) and typically 18 months or more for rifampicin-resistant TB (RR-TB). Globally, the treatment
success rate for RR-TB is approximately 50%; about one in seven RR-TB patients is lost to follow-up
during treatment [14]. It is highly relevant to identify which programmatic solutions could contribute to
improved TB treatment adherence, and ultimately lead to better patient outcomes.
For example, enhanced communication via SMS or video calls could strengthen relationships between
patients, families and healthcare providers, and promote retention in care as well as treatment adherence.
Early detection of missed treatment doses (e.g. by electronic MMs) could allow healthcare workers to
address any patient concerns or barriers, to suggest specific steps to improve adherence, and to mitigate
potential loss to follow-up. Similarly, early signalling to healthcare providers of potential drug side-effects
could allow for treatment changes and/or effective symptomatic management.
The use of digital health applications to improve treatment support for active TB patients also appeals to
TB programme managers, because of affordable mobile electronic devices in many settings. The potential
of these technologies to support patient-centred interventions, a key element of the End TB Strategy, has
been recognised in recent years by the World Health Organization (WHO) [16–18].
Digital interventions are gradually being integrated into practice, and are tested and evaluated in field trials
focused specifically on TB prevention and care [19]. SMS and other technologies which can communicate
via cellular or internet networks, such as video-observed therapy (VOT) and the Medication Event
Monitoring System and other electronic medication monitors (MMs), are being employed. For example,
VOT was first used for TB in 2007 in several clinical programmes in London, UK, as an alternative to
in-person treatment observation [20]; it has also been evaluated in studies in Australia, the USA and
Mexico [21–23].
Although several evaluations involving TB patients have now been completed, a comprehensive review of
the role of digital technologies in improving TB care has not been performed. We reviewed the published
literature to determine whether digital technologies were effective at improving TB treatment adherence,
and treatment outcomes (e.g. completion, cure, loss to follow-up) as defined by the WHO [24].
Methods
Cochrane guidelines for systematic reviews of interventions were followed [25].
Search strategy
In July 2016, using search terms to denote TB disease, digital technologies and TB treatment outcomes, we
searched for relevant studies from the following bibliographical databases: MEDLINE/PubMed, EMBASE,
Cochrane Library of Trials, and Web of Science, as well as clinicaltrials.gov and Journal of Global Health,
Journal of Telemedicine and Telecare and the Journal of Telemedicine and e-Health. WHO databases and
reports were also searched. Given the dearth of published studies, we included unpublished literature when
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full results had been provided to the WHO and were available from its databases. The complete list of
search terms is provided in supplementary table S1. We set no restrictions in terms of language or
publication dates.
Study selection; inclusion and exclusion criteria
After the preliminary search, two authors (B.K. Ngwatu and N.P. Nsengiyumva) independently screened
all titles and abstracts for eligibility. Upon initial review, any studies not related to digital health
interventions for TB treatment support were excluded.
We then conducted a detailed review of the remaining abstracts and full text articles. Specifically, we
included studies that reported on digital health technology interventions supporting active TB treatment,
such as SMS reminders, VOT and MMs, and compared them to the local standard of care as defined by
the authors, with no additional specific intervention.
We included randomised controlled trials (RCTs) and observational studies, if they had a control group
and reported the effect of digital technologies on adherence to treatment or appointments, and/or any of
the following standard TB treatment outcomes: cure, treatment success (cure or treatment completed)
[24], loss to follow-up from treatment, or a combination of unfavourable outcomes, including death,
failure and/or loss to follow-up.
We excluded studies that did not report an estimate of effect related to the intervention, and those that did
not report a study end-point of relevance to our review’s objective (i.e. those that only reported TB
incidence, number of secondary TB cases, costs for patients and services, patient acceptability and
feasibility). We excluded reports that only described study protocols, those where only an abstract was
available, letters, editorials and position papers. If the same study was reported in different publications,
we considered only the most recent publication.
Data extraction
Two reviewers (B.K. Ngwatu and N.P. Nsengiyumva) extracted data from relevant articles into a
standardised template, with the following information: authors, study design, method/description (title,
aim, primary and secondary outcomes and duration of study), publication year, country, target population
characteristics (numbers, age and sex distribution, smear status), type of digital health intervention,
comparator (DOT, or no specific intervention) and measures of effect (means ratios, risk ratios, or odds
ratios with respective confidence intervals). Data were then reviewed and discussed with additional
reviewers (O. Oxlade, K. Schwartzman, D. Falzon and B. Mappin-Kasirer).
Quality assessment of studies
We assessed the risk of bias in the RCTs using the Cochrane risk-of-bias 2.0 (RoB 2.0) tool [26] and
reported on selection bias, performance bias, detection bias, attrition bias and reporting bias. For each
feature of interest, three scores were used: low risk, high risk and unclear risk.
Selection bias in RCTs was assessed by examining whether proper sequence generation and concealment
of allocation sequence were carried out. Performance bias was evaluated by reviewing the blinding of
participants and/or investigators administering the interventions. Detection/outcome measurement bias
was assessed by reviewing who was aware of the intervention received by study participants. Bias due to
attrition or incomplete or missing outcome data was evaluated by looking at whether outcome data was
available for all, or nearly all, participants. Reporting bias was assessed by the extent to which the authors
appeared to report their results in the way they had originally proposed in their protocols.
For observational studies, we adapted the ROBINS-I (risk of bias in non-randomised studies of
interventions) tool [27] to assess selection bias, bias due to confounding, bias due to missing data, and
bias in measurement of outcomes. We used the same scoring system as for RCTs.
Results
Study selection
Our search initially identified 342 studies (figure 1). Screening of titles yielded 57 (17%) relevant studies
after eliminating 24 duplicates, 33 studies were retained.
Excluded studies
After screening the 33 abstracts, nine studies (27%) were excluded: two study protocols, two systematic
reviews, three ongoing studies, and two feasibility studies (a microchip system with an ingestible sensor,
and a voice call based reminder system for adherence).
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After full-text review of the 24 articles, 17 (71%) were excluded: seven used end-points that differed from
our primary end-points of interest, three had no control group, four reported only qualitative outcomes,
two focused only on costs, and one was an ongoing study.
Details of the excluded studies are provided in supplementary table S2.
Included studies
Ultimately, seven studies were retained: three observational studies and four RCTs. All seven had a control
group and provided estimates of effect: one evaluated MMs [28], three evaluated SMS reminders [29–31],
two examined VOT [22, 23] and one examined the combination of SMS and MM [32]. The studies were
carried out in seven geographically diverse settings: Argentina, Australia, Cameroon, China, Pakistan,
South Africa and the USA [22, 23, 28–32]. Details of these seven studies, including details of the
intervention evaluated, are listed in table 1.
Findings
Detailed results for each intervention studied are shown in table 2. Treatment adherence is reported as
described in the articles. Most often it was based on the number of expected doses actually taken, but
sometimes on the retention of patients during the study period.
MM
A South African pilot study reported a risk ratio of 2.3 (95% CI 1.6–3.4) [28] for improvement in cure rates,
but the comparison group was a historical, non-concurrent control group. This study also suggested
significant improvement in smear conversion at 2 months, with risk ratio 1.62 (95% CI 1.09–2.42), although
again the control group was historical (non-concurrent). A larger RCT in China reported a statistically
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FIGURE 1 PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram for
selection of studies.
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TABLE 1 Details of studies included in this systematic literature review
Digital intervention Objective Method/ study
design/ location
Subjects n Intervention Standard of care
in control arm
Electronic medication
monitors
BROOMHEAD [28] To evaluate cost
implications and
health outcomes of
the implementation of
SIMPill, in new
smear-positive TB
patients receiving TB
medication
A single-arm trial,
with retrospective
analysis of data from
TB patients (historic
controls) at a clinic
in Northern Cape
Province, South
Africa
120 participants
(24 intervention, 96
in historic control
arm), new
smear-positive TB
SIMPill a pillbox which,
when opened, sends an
SMS to a server,
indicating that the
patient has taken their
medication
DOT#
SMS reminders
BEDIANG [31] To evaluate the
effectiveness of SMS
reminders as an
adjunct to DOT in
improving TB
treatment adherence
and success.
Randomised,
concealed,
single-blinded
controlled trial
conducted at 12 TB
treatment centres
in Yaoundé,
Cameroon
279 patients with
active TB (137 in
intervention group,
142 in control
group)
One-way SMS; daily
reminders for TB
medication as adjunct to
DOT
DOT#
IRIBARREN [29] To evaluate the
acceptance and
feasibility of a
patient-based text
intervention to
promote their
adherence to TB
treatment
Randomised,
concealed
non-blinded
controlled trial,
conducted within a
specialised hospital
in Buenos Aires,
Argentina
37 newly diagnosed
TB patients (18 in
intervention group,
19 in control group)
Two-way SMS; patients
were instructed to SMS
the clinic after
self-administration of
medication as a proxy of
adherence (they received
reminders if they did not
send a message)
SAT
MOHAMMED [30] To measure the
impact of a two-way
SMS reminder system
on TB treatment
outcomes
Randomised,
non-blinded
controlled trial at TB
treatment facilities
in Karachi, Pakistan
2207 newly
diagnosed TB
patients (1110 in
intervention arm,
1097 in control
arm)
Two-way SMS; daily
automated SMS
reminders sent at
prescheduled time
Patient responds
back via SMS or
phone call
DOT#
Video-observed
therapy
CHUCK [22] To determine whether
video technology for
remote observation of
patients on anti-TB
treatment (VOT) is as
effective as in-person
DOT
Prospective cohort
study
390 patients using
DOT for TB
treatment support,
New York, USA
61 patients (16%)
were assigned to
VOT and 329 (84%)
to in person DOT
VOT worker and patient
pre-arranged a schedule
for the VOT calls
DOT#
WADE [23] To assess the
effectiveness related
to patient
compliance, cost
effectiveness,
acceptability and
sustainability of
video-based DOT
A retrospective
cohort design was
used, recipients of
VOT were compared
to in-person-DOT
recipients using data
at a facility in
Adelaide, South
Australia
128 patients with
active TB at the
community nursing
service (58 in
intervention group,
70 in control group)
VOT; patients received
daily video calls from the
facility
DOT*
Continued
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significant effect on adherence with a MM relative to standard care, with an adjusted means ratio of 0.58 for
percentage of patient-months where at least 20% of doses were missed (95% CI 0.42–0.79) [32].
SMS
Four RCTs [29–32] evaluating SMS as medication reminders showed no statistically significant effect on
treatment completion, when compared with the local standard of TB care. In three of these [23, 24, 26],
the risk ratios for completion, success or cure ranged from 1.0–1.45, and the 95% CI fell within these
values in all three trials. In the SMS arm of the fourth trial [25], compared to standard care the adjusted
risk ratio for failure, death, and loss to follow-up combined was 0.44 (95% CI 0.17–1.13). In the same four
studies, SMS reminders were found to have very little to no, impact on TB medication doses taken, with
risk or means ratios approaching 1. Three of the four studies [23–25] employed two-way text messaging
between patients and providers, while one study used one-way text reminders to patients [26].
VOT
One study in New York City (NY, USA) reported a risk ratio of 0.99 (95% CI 0.93–1.05) for treatment
completion with VOT compared with in-person DOT, although it also reported a positive effect on
appointment attendance (95% adherence to scheduled VOT sessions compared to 91% of scheduled DOT
visits) [22]. Another study in Australia reported a higher proportion of observed treatment doses with
VOT compared to in-person DOT, but the effect on treatment completion rates was not statistically
significant [23]. In both studies, VOT substantially reduced the personnel time needed for treatment
supervision. These studies used synchronous (videoconferencing) technology, which might have a different
effect on adherence compared with asynchronous (recorded) VOT [21].
SMS and MM
The RCT in China [25] included an additional arm that combined both two-way SMS and MM used as
medication dose reminders; there was potential synergy in that the adjusted means ratio for percentage of
patient-months where at least 20% of doses were missed was 0.49 (95% CI 0.27–0.88). In that study, 14%
of participants in the combined intervention arm missed 20% or more doses, compared to 30% in the
control arm [32].
Assessment of methodological quality
Quality assessment and risk of bias in the randomised trials reviewed are shown in table 3. We found low
selection bias, as all publications of randomised trials provided information about the processes of random
sequence generation and/or allocation concealment in the studies. Overall, there was high bias of
performance across the trials. Detection/outcome measurement bias was high for one trial since the
TABLE 1 Continued
Digital intervention Objective Method/ study
design/ location
Subjects n Intervention Standard of care
in control arm
SMS reminders,
medication/
electronic monitors
(evaluated alone or
in combination)
LIU [32] To evaluate the
effectiveness of text
messaging and
medication monitors
in improving TB
medication
adherence
Cluster randomised
trial (using
stratification and
restriction)
conducted in four
provinces in China
4173 TB patients
(1104 control, 1008
SMS arm, 997 MM
arm, 1064
combined SMS and
MM)
Two-way SMS, MM or
combination of two-way
SMS and MM reminders
on dose days to take
medicine and to attend
follow-up visits
Physicians were advised
to provide more active
follow-up to patients
with adherence issues
DOT# and MM
without reminders
TB: tuberculosis; MM: medication monitor; SMS: short message service; DOT: directly observed treatment; SAT: self-administered treatment.
#: patients on in-person DOT were defined as those who had doses of medication observed at a health department or hospital clinic or in the
community, and did not receive the intervention being evaluated in the study. Depending on the study, some treatment doses in the “DOT” arm
were, in fact, self-administered.
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assessors were aware of the intervention received by study participants, while in the remaining three trials
it was unclear. Studies varied with respect to attrition bias. We found low reporting bias in three of the
trials; we could not evaluate one of the trials as the trial protocol was not available. Further details of the
quality assessment for the randomised trials are in supplementary table S3 and supplementary figures S1
and S2.
TABLE 2 Impact of digital health interventions on study outcomes: intervention versus control groups
First author
[ref.]
Intervention Subjects n
control:
intervention
Study outcome (definition) Findings in
control group/
standard care %
Findings in
intervention
group%
Measure of effect
(95% CI)
BROOMHEAD [28] MM# 96:24 Smear conversion rate at
2nd month
38 63 RR: 1.62 (1.09–2.42)
Cure rate: negative sputum
smear in last month of
treatment
32 75 RR: 2.32 (1.60–3.36)
BEDIANG [31] SMS 142:137 Treatment success rate
(assessed at 5th month)
75 81 RR: 1.45 (0.81–2.56)
Cure rate 62 64 RR: 1.06 (0.65–1.73)
Drop-out proportion, 6th
month
32 34 RR: 1.08 (0.77–1.51)
IRIBARREN [29] SMS 19:18 Adherence: self-reported
adherence (booklets/
calendars versus SMS)¶
53 77 Not calculated¶
Treatment success: cured
or completed treatment
90 94 RR: 1.06 (0.87–1.28)
MOHAMMED [30] SMS 1097:1110 Treatment success: cured
or completed treatment
83 83 RR: 1 (0.96–1.04)
Completed: completed
treatment but does not
have a negative smear
30 30 RR: 1 (0.79–1.26)
Cure: sputum smear or
culture-negative in the last
month
53 53 RR: 1 (0.90–1.12)
CHUCK [22] VOT 329:61 Treatment completion 97 96 RR: 0.99 (0.93–1.05)
Adherence: appointment
compliance (visits
attended)+
91 95 RR: 1.05 (1.04–1.06)
WADE [23] VOT 70:58 Treatment completion 33 48 RR: 1.47 (0.96–2.25)
Adherence: observed
doses§
69 88 Not calculated##
LIU [32] MM 1091:992 Non-adherence: months
with at least 20% of doses
missedƒ
30 17 aMR: 0.58 (0.42–0.79)
SMS 1091:996 Non-adherence: months
with at least 20% of doses
missedƒ
30 27 aMR: 0.94 (0.71–1.24)
MM and
SMS
1091:1059 Non-adherence: months
with at least 20% of doses
missedƒ
30 14 aMR: 0.49 (0.27–0.88)
MM 1066:955 Poor treatment outcome:
failure, death and LTFU
9 6 aRR: 0.71 (0.33–1.51)
SMS 1066:966 Poor treatment outcome:
failure, death and LTFU
9 4 aRR: 0.44 (0.17–1.13)
MM and
SMS
1066:992 Poor treatment outcome:
failure, death and LTFU
9 9 aRR: 1.00 (0.45–2.20)
MM: medication monitor; RR: risk ratio; SMS: short message service; VOT: video-observed therapy; aMR: adjusted means ratio; LTFU: loss to
follow-up; aRR: adjusted risk ratio. #: historical control; ¶: adherence comparison between the intervention and control groups is hampered by
the fact that 47% of the calendars were not returned for analysis; +: 3292 (95%) out of 3455 sessions scheduled for patients on VOT were
successfully attended, compared to 32204 (91%) out of 35442 among patients on in-person DOT; §: calculated using data provided in original
text articles; ƒ: mean of the percentage of patient-months on TB treatment where at least 20% of doses were missed; ##: could not be
calculated, as no risk ratios were reported in the article and absolute numbers were not provided.
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Quality assessment and risk of bias in the observational studies is shown in table 4. Selection bias could
not be assessed, but there was high risk of bias due to confounding in most studies as demographic
characteristics, disease severity, socioeconomic status and other confounding factors were not evaluated or
accounted for. Outcome measurement bias was also high since the assessors were aware of interventions
received by study participants. Bias due to missing data varied. We could not evaluate reporting bias as the
study protocols were not available.
Discussion
Digital health interventions are increasingly used to support TB treatment in diverse settings globally.
Studies in this review suggest that some digital interventions can potentially improve medication
adherence and patient outcomes. While evidence remains incomplete, and generalisability limited, the
studies reviewed suggest these technologies may be at least as effective as the standard of care. Compared
with direct in-person treatment observation, VOT and MM technologies may improve efficiency, save
money and reduce burden on patients and healthcare workers. VOT used for treatment observation in
London, UK, led to improved communication between patients and providers [20, 33]. Pilot single-arm
VOT studies in the USA, Mexico and Belarus suggested that treatment outcomes were comparable to
those with in-person DOT, with markedly reduced health system costs [21, 34]. These studies compared
VOT to high-functioning DOT programmes; there was no difference in adherence, which suggests that
comparably high adherence can be obtained using digital technologies for treatment support. In settings
where digital solutions cost less and/or are easier to implement and use than the standard of care, VOT
may be a beneficial alternative. Along similar lines, a pilot study of MM use in South Africa [28] suggested
substantial return on investment through improved treatment outcomes and cost savings.
SMS studies in this review showed no significant effect on clinical treatment outcomes and adherence,
though there was weak evidence of an impact on loss to follow-up during treatment. Results from three
large RCTs of one- or two-way SMS during TB treatment [30–32] contrast with evidence from
meta-analyses of RCTs in other disease settings. For example, studies have shown a positive effect of
two-way SMS on HIV treatment adherence and treatment outcomes [35–37]. One potential explanation
for this difference is that SMS communication and support add more to self-administered treatment (as is
the case for HIV) than to direct observation and in-person treatment support, as is done in
well-functioning TB programmes.
More generally, where DOT is systematically well delivered, digital technologies such as VOT and MMs
are unlikely to improve adherence or clinical outcomes, but can substantially bolster efficiency and
convenience for patients and providers. In TB treatment contexts where DOT is not effectively delivered,
digital technologies offer the possibility of improving adherence and clinical outcomes, though suitable
evidence is needed. An important example is latent TB infection, where most treatment is currently
self-administered.
The application of mobile phone interventions to help TB efforts continues to generate interest. After we
completed this systematic review, two RCTs were completed. A study of SMS reminders used among TB
TABLE 3 Quality assessment/risk of bias of randomised trials included in the review
First author [ref.] Selection bias Performance bias Detection bias Attrition bias Reporting bias
BEDIANG [31] Low High High Low Low
IRIBARREN [29] Low High Unclear High Unclear
MOHAMMED [30] Low High Unclear Low Low
LIU [32] Low High Unclear Low Low
TABLE 4 Quality assessment/risk of bias of observational studies included in the review
First author
[ref.]
Selection
bias
Confounding Measurement of
outcome
Missing
data
Reporting
bias
BROOMHEAD [28] Unclear High High Low Unclear
CHUCK [22] Unclear High High Low Unclear
WADE [23] Unclear High High Unclear Unclear
https://doi.org/10.1183/13993003.01596-2017 8
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patients in China described improved treatment completion and fewer missed doses with daily one-way
SMS reminders [38]. The results of another RCT, in Kenya, investigating treatment support and
supervision built around daily two-way SMS communication, are not yet published, but the protocol is
available online [39].
Until recently, the evidence base underpinning the use of digital interventions to support TB care has
relied largely on experience in other disease contexts. Although a systematic review of studies examining
the effect of SMS technology on TB treatment adherence was published in 2013 [40], our systematic
review, to our knowledge, is the first to consider studies evaluating the effect of several digital health
technologies on TB treatment adherence and treatment outcomes. Since 2015, the World Health
Organization (WHO), the European Respiratory Society, and other leading technical and funding partners
have developed target product profiles for digital health interventions to help steward the implementation
and evolution of these potentially useful tools [19]. The latest WHO TB treatment guidelines highlight the
potential contributions of SMS, VOT and MMs in supporting adherence and treatment delivery for
patients and programmes [18]. This policy now needs to be complemented by additional evidence as well
as by pragmatic implementation guidance, to enable users to translate research findings into local practice.
Our review has several limitations. We focused on quantitative comparisons of adherence and clinical
outcomes, as these are fundamental to the evidence base. For this reason, we have not provided a detailed
review of studies which focused exclusively on cost, feasibility, acceptability and/or qualitative assessments.
However, these are also essential in considering introduction and scale-up of such technologies, and in
supplementary table S2, we provide suitable references to such studies.
Despite an extensive search, we only found seven relevant reports. Given the marked heterogeneity of
study designs, end-points and settings, we were unable to pool the estimates of effect, and could only
summarise findings as reported from each of the seven studies. It was difficult to fully characterise the
methodological quality of some studies, as the necessary information was often incompletely reported.
This should be kept in mind when interpreting study results. Finally, a recurrent limitation of the existing
literature is the emphasis on short-term measures of medication adherence, e.g. missed doses. The
relationship of such measures to relevant clinical outcomes for patients and providers is not always certain.
With the growing interest in mobile technologies and the increasing affordability and global expansion of
broadband internet and mobile phones [11], further evaluation of digital health interventions is urgently
needed – ideally in adequately powered RCTs, or at a minimum, in observational studies with adequate
sample size, suitable controls, and appropriate TB treatment outcomes as study end-points. Practices such
as registering and publishing study protocols a priori, and using reporting guidelines such as CONSORT
(consolidated standards for reporting trials) for RCTs, can improve the quality of the evidence. Currently
there are several ongoing or unpublished RCTs evaluating clinical outcomes of TB treatment which apply
these technologies in diverse settings; their protocols are available online [31, 33, 39, 41–43]. Beyond
RCTs, further research on implementation is needed to evaluate and understand the feasibility,
acceptability and cost of the various digital health interventions in diverse communities and locations. It
will be relevant to explore the possible influence of digital technologies on behaviour change at other
points on the patient pathway – for example, in preventing initial loss-to-follow-up before TB treatment
initiation, or in detecting and managing adverse events during treatment [44].
In conclusion, the evidence base from studies on digital technologies targeting TB is slowly growing.
Despite interest in the use of digital technologies to improve the care of persons with TB, their reported
impact has been variable and evidence from implementation studies remains sparse. Our findings suggest
that certain digital technologies can support TB treatment efforts while reducing both patient and provider
costs, as well as patient inconvenience. Worldwide, patients and providers are increasingly using mobile
devices to communicate. It is thus important to understand how technologies could best be used to
provide better patient-centred treatment support and to allocate resources more judiciously. Data from
ongoing and future research, including non-inferiority studies, pragmatic trials and cost-effectiveness
analyses, will aid in the optimisation of practical approaches. These could include targeting different entry
points on the behaviour change pathway which have not yet been explored, and combining several
technologies – either sequentially or simultaneously – to better leverage their effects on TB treatment
adherence, and ultimately, clinical outcomes.
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